Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Consensus Price Target from Brokerages

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been assigned an average recommendation of “Hold” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $3.33.

Separately, StockNews.com initiated coverage on Syros Pharmaceuticals in a research note on Thursday, March 13th. They issued a “sell” rating for the company.

Syros Pharmaceuticals Price Performance

Shares of SYRS opened at $0.11 on Tuesday. The stock has a 50-day moving average of $0.16 and a 200-day moving average of $0.87. The company has a market cap of $2.82 million, a PE ratio of -0.03 and a beta of 1.31. Syros Pharmaceuticals has a one year low of $0.07 and a one year high of $6.93.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Exome Asset Management LLC boosted its stake in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares during the last quarter. Two Sigma Securities LLC purchased a new position in shares of Syros Pharmaceuticals in the 4th quarter worth approximately $25,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Syros Pharmaceuticals in the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.